Nov 17, 2022 / 03:15PM GMT
Dave Stanton - Jefferies LLC - Analyst
Good afternoon, everyone. Welcome to another afternoon session of the Jefferies London Healthcare Conference. My name is Dave Stanton. I'm part of the Jefferies Australia healthcare research team. It's my absolute pleasure to be hosting Telix today. And Dr. Chris Behrenbruch, CEO of Telix, is with us.
We thought we'd start with a presentation, get everybody up to date on the company. And then it's a chat after that. So if anybody has got any questions, please raise your hand and it will either be a microphone come around or you can just repeat the question back to me.
Chris, thanks very much, and over to you.
Chris Behrenbruch - Telix Pharmaceuticals Limited - MD, CEO
Yeah, thanks, Dave. Really appreciate it, and thanks to the Jefferies team for the opportunity to present to you today. I'm just going to give a few introductory slides. We're not a super widely known company yet. So it's an opportunity for me to give you a bit of background.
We are a radiopharmaceutical company, one of the leading
Telix Pharmaceuticals Ltd at Jefferies London Healthcare Conference Transcript
Feb 15, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers